Canaccord Genuity Starts Halozyme Therapeutics (HALO) at Buy
Get Alerts HALO Hot Sheet
Price: $40.73 --0%
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 10
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 10
Join SI Premium – FREE
Canaccord Genuity initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $8.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Starts SI-BONE Inc. (SIBN) at Overweight, 'would recommend investors own the name'
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK185 at Telsey, 'encouraged by the topline momentum'
- William Blair Starts Solid Biosciences (SLDB) at Outperform, 'success in any of programs alone should provide severalfold upside from Solid’s current valuation'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!